Intrauterine growth restriction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes intrauterine growth restriction compared with placebo (very low certainty).
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the child ‐ Congenital malformations compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
All VTE · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (moderate certainty).
1 finding from 1 review
Intervention not reported
Proximal DVT · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower proximal DVT (moderate certainty).
1 finding from 1 review
Intervention not reported
Symptomatic VTE · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in symptomatic VTE (moderate certainty).
1 finding from 1 review
Intervention not reported
Bleeding complications · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in bleeding complications (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).
2 findings from 1 review
Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.
LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review
Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review